Compare Novo Nordisk A/S (NVO) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Palantir Technologies Inc — how do they compare? Novo Nordisk A/S trades at $45.8 (market cap $207.85B), while Palantir Technologies Inc trades at $173.58 (market cap $420.39B). The key difference: Palantir Technologies Inc is far larger — about 2× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.
| NVO | PLTR | |
|---|---|---|
Market Cap | $207.85B | $420.39B |
Sector | Health | Technology |
52-Week High | $63.98 | $207.18 |
52-Week Low | $35.29 | $107.27 |
Enterprise Value | $222.55B | $411.19B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Palantir (PLTR) trades at $175.20, up 1.85% with strong bullish technical signals and consistent earnings beats. The stock shows impressive fundamental growth with revenue reaching $4.48 billion in 2025 and net income margin expanding to 36.3%. Recent quarterly EPS results have exceeded expectations, driving positive investor sentiment despite elevated valuation multiples. Technical indicators show bullish momentum with the current price near pivot point resistance at $175.
Outlook remains positive with accelerating revenue growth and expanding margins, though high valuation ratios (P/E 149.52, P/S 73.07) present risk. Analyst consensus targets $213.44 with 50% buy ratings, but insider selling and Michael Burry's bearish stance highlight caution. The stock offers growth potential but requires monitoring of execution risks and competitive pressures in the AI software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
